On November 11, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (Adcetris), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for brentuximab vedotin.

“The approval of brentuximab vedotin for young people with high risk classical Hodgkin lymphoma offers access to these patients to a new treatment option,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “We are hopeful that this approval will continue to improve treatment strategies and options for children and adolescents with this disease.”

For more information on the FDA approval of brentuximab vedotin (Adcetris), visit the FDA’s website.  To learn more about treatment options for HL visit the HL Learning Centers.